New pill hopes to slow Alzheimer's in major trial
Disease control
Not yet recruiting
This Phase 3 study tests whether MLC901 (NeuroAiD II) can slow cognitive decline in people with mild to moderate Alzheimer's disease. About 350 participants will receive either the drug or a placebo for several months. Researchers will measure changes in memory, thinking, and dai…
Phase: PHASE3 • Sponsor: Moleac Pte Ltd. • Aim: Disease control
Last updated May 17, 2026 04:17 UTC